logo

For the Inventor, By the Inventor

Port Jefferson, NY, United States of America

Thomas F McNamara

This inventor holds 26 USPTO granted patents, primarily in Pharmaceutical Innovations. Top assignees: The State University of New York, Hospital for Joint Diseases, University of Miami. Active years: 1986-2002.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Thomas F McNamara. Retrieved from https://idiyas.com/inventor/thomas-f-mcnamara

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26

% Patents Active = 100.0

Average Co-Inventor Count = 3.4

ph-index = 21

Forward Citations = 898(Granted Patents)


Location History:

  • New York, NY (US) (1997)
  • Port Jefferson, NY (US) (1986 - 2000)
  • Morristown, NY (US) (2002)

Company Filing History:

goldMedal22 out of 2,046 
 
The State University of New York
 patents
silverMedal2 out of 14 
 
Hospital for Joint Diseases
 patents
bronzeMedal2 out of 391 
 
University of Miami
 patents
4. 1 out of 1,872 
 
Kuraray Co., Ltd.
 patents
5. 2 out of 834,513 
Other
 patents
where one patent can have more than one assignee

Years Active: 1986-2002

Loading Chart...
Areas of Expertise:
Cancer Inhibition
Diabetes Management
Wound Healing
Tetracycline Compounds
Phospholipase A.sub.2
Muscle Protein Degradation
Collagenolytic Enzymes
Non-Steroidal Anti-Inflammatory Agents
Dental Compositions
Connective Tissue Destruction
Metabolic Characteristics
Antiplaque Compositions
26 patents (USPTO):Explore Patents
1. 6429204 - Method of inhibiting cancer growth (2002-08-06),
2. 6100248 - Method of inhibiting cancer growth (2000-08-08),
3. 6043231 - Inhibition of excessive phospholipase A.sub.2 activity and/or production (2000-03-28),
4. 5929055 - Therapeutic method for management of diabetes mellitus (1999-07-27),
5. 5919775 - Method for inhibiting expression of inducible nitric oxide synthase with (1999-07-06),
6. 5837696 - Method of inhibiting cancer growth (1998-11-17),
7. 5827840 - Promotion of wound healing by chemically-modified tetracyclines (1998-10-27),
8. 5789395 - Method of using tetracycline compounds for inhibition of endogenous (1998-08-04),
9. 5770588 - Non-antibacterial tetracycline compositions of the prevention and (1998-06-23),
10. 5662561 - Weighted handle for a jump rope (1997-09-02),
11. 5532227 - Tetracyclines including non-antimicrobial chemically-modified (1996-07-02),
12. 5523297 - Inhibition of excessive phospholipase A.sub.2 activity and/or production (1996-06-04),
13. 5459135 - Composition comprising indomethacin [non-steroidal anti-inflammatory (1995-10-17),
14. 5321017 - Composition comprising fluriprofen and effectively non-antibacterial (1994-06-14),
15. 5308839 - Composition comprising non-steroidal anti-inflammatory agent tenidap and (1994-05-03),

Title: The Innovative Mind of Thomas F McNamara

Introduction:

Thomas F McNamara, a prolific inventor based in Port Jefferson, NY, has made significant contributions to the field of cancer research through his groundbreaking patents. With an impressive portfolio of 26 patents, McNamara's work has focused on developing methods to inhibit cancer growth in mammals using novel compounds.

Latest Patents:

McNamara's latest patents showcase his innovative approach to combating cancer. His method of inhibiting cancer growth involves the use of 6-demethyl-6-deoxy-4-de(dimethylamino)tetracycline (CMT-3) to target and inhibit sarcomas, such as Kaposi's sarcoma, in mammals. Additionally, he has developed a method to inhibit cancer growth by targeting cellular proliferation, invasiveness, and metastasis, using chemically modified tetracycline compounds.

Career Highlights:

Throughout his career, McNamara has made significant strides in the field of oncology. He has been associated with reputable institutions such as The Research Foundation of the State University of New York and the Hospital for Joint Diseases. His relentless pursuit of innovative solutions has led to the development of patents that have the potential to revolutionize cancer treatment.

Collaborations:

McNamara has collaborated with esteemed colleagues in his research endeavors. Notable coworkers include Lorne M Golub and Nungavaram S Ramamurthy, who have worked alongside him to advance the field of cancer research. Their collective efforts have resulted in patents that hold promise for the future of cancer therapy.

Conclusion:

In conclusion, Thomas F McNamara stands as a beacon of innovation in the realm of cancer research. His passion for discovering new ways to combat this complex disease is evident in his extensive patent portfolio. Through his collaborations and career achievements, McNamara has solidified his place as a pioneering inventor at the forefront of cancer treatment innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…